Is platinib effective in treating prostate cancer?

Platinib, as a therapeutic drug targeting RET gene mutations, has achieved certain results in the field of cancer treatment. Platinib mainly works by inhibiting abnormal signaling of the RET receptor, a mechanism that has been verified in non-small cell lung cancer and thyroid cancer. But in prostate cancer, the frequency of RET gene mutations is relatively low, which means platinib may only be effective in a small proportion of prostate cancer patients.

Currently, there are relatively few clinical studies on platinib in the treatment of prostate cancer. Existing research has mainly focused on prostate cancer patients with positive RET gene fusions or mutations, and these patients account for a small proportion of the overall prostate cancer population. Therefore, it is difficult to draw generalizable conclusions from existing clinical studies.

In published clinical data, platinib has shown certain efficacy in prostate cancer patients with RET gene fusions or mutations. For example, in some case reports or small studies, platinib can reduce tumor size, relieve cancer-related symptoms, and extend patients' progression-free survival. However, these results need to be further verified in large-scale, randomized controlled clinical trials.

In addition to efficacy, we also need to pay attention to the safety of platinib. In known studies, the side effects of platinib mainly include hypertension, abnormal liver function, etc. These side effects may also occur in patients with prostate cancer. Therefore, when using platinib to treat prostate cancer, its efficacy and safety need to be weighed.